Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival - Topp, M S; Kufer, P; Gokbuget, N (J Clin Oncol, 2011)
et al.